Produção Nacional
Revisado por pares
Crizanlizumab for the Prevention of Pain Crises in Sickle Cell Disease
2016; Massachusetts Medical Society; Volume: 376; Issue: 5 Linguagem: Inglês
10.1056/nejmoa1611770
ISSN1533-4406
AutoresKenneth I. Ataga, Abdullah Kutlar, Julie Kanter, Darla Liles, Rodolfo Delfini Cançado, João Ricardo Friedrisch, Troy H. Guthrie, Jennifer Knight‐Madden, Ofelia Álvarez, Victor R. Gordeuk, Sandra Gualandro, Marina Colella, Wally R. Smith, Scott A. Rollins, Jonathan W. Stocker, Russell P. Rother,
Tópico(s)Blood groups and transfusion
ResumoThe up-regulation of P-selectin in endothelial cells and platelets contributes to the cell–cell interactions that are involved in the pathogenesis of vaso-occlusion and sickle cell–related pain crises. The safety and efficacy of crizanlizumab, an antibody against the adhesion molecule P-selectin, were evaluated in patients with sickle cell disease.
Referência(s)